Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2021 | $2.00 | Buy | Roth Capital |
| 8/19/2021 | $3.50 → $2.50 | Buy | Aegis Capital |
SC 13D/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
SC 13G/A - MARRONE BIO INNOVATIONS INC (0001441693) (Subject)
Roth Capital initiated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.00
Aegis Capital reiterated coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $2.50 from $3.50 previously
Canaccord Genuity resumed coverage of Marrone Bio Innovations with a rating of Buy and set a new price target of $3.50
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K Annual Report; and (b) June 28, 2021. The Board also changed the effective dates of the appointments of Russell T. Ray, MBA and Teresa DeLuca MD, MBA as members of the Board, as previously announced
DAVIS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that Suping (Sue) Cheung has been appointed chief financial officer, effective Feb. 18, 2021. She succeeds James Boyd, who previously announced his intention to retire. Cheung, a certified public accountant, brings to Marrone Bio 28 years of experience in international strategic and financial operations, including financial reporting, forecasting and budgeting; mergers and acquisitions; equity and debt financing; internal controls; and inves
RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the low- to mid-teens on a percentage basis.Gross profit of $6.2 million and gross margins of 55.9% reflected changes in product mix, higher raw material
RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations' first quarter financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information: Q1 2022 Conference Call and Webcast Date: Wednesday, May 11, 2022Time: 4:30 p.m
RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.As announced March 16, 2022, Marrone Bio and Bioceres Crop So
ROTH MKM ("Roth"), www.roth.com, a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group has advised on three sellside transactions in the past nine months. The transactions included business models in the areas of cover crops, gene editing, biologicals, bio stimulants, and alternative fertilizers, and demonstrate the group's expertise in designing and executing M&A processes to achieve the best outcomes for its clients in a wide array of agriculture related sectors. ROTH MKM's Agribusiness Investment Banking Group served as the sellside advisor on the following transactions:
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today the successful completion of its previously announced integration of Marrone Bio Innovations, Inc. (NASDAQ:MBII) ("MBI"). "The completion of this transaction represents an important milestone in our journey, cementing our leadership in the development and commercialization of sustainable agricultural solutions," said Bioceres Chief Executive Officer, Federico Trucco. "MBI brings 15 years of experience in the development of biological solutions, and we are excited to a
RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by t
15-12G - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
EFFECT - Pro Farm Group, Inc. (0001441693) (Filer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)
4 - MARRONE BIO INNOVATIONS INC (0001441693) (Issuer)